CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. This represents a 0.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Xingjuan Chao also recently made the following trade(s):
- On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The stock was sold at an average price of $15.03, for a total value of $50,681.16.
CeriBell Trading Down 1.1 %
NASDAQ CBLL opened at $14.77 on Wednesday. The stock's 50-day simple moving average is $20.02. CeriBell has a one year low of $10.01 and a one year high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. Research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts recently commented on CBLL shares. LADENBURG THALM/SH SH started coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $32.50.
View Our Latest Stock Analysis on CBLL
Hedge Funds Weigh In On CeriBell
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in shares of CeriBell in the fourth quarter valued at about $128,120,000. TPG GP A LLC bought a new stake in CeriBell in the 4th quarter valued at approximately $102,677,000. Red Tree Management LLC acquired a new position in CeriBell during the 4th quarter worth approximately $57,083,000. Yu Fan bought a new position in shares of CeriBell during the 4th quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $28,160,000.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
